Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSPIRE trial of felzartamab for late isolated microvascular inflammation after kidney transplantation
2025-521742-15-00Phase 2Authorised
- Sponsor
- Biogen
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in kidney allograft rejection and microvascular inflammation (MVI) comparing Felzartamab with Placebo (2 arms). Primary endpoint: Percentage of participants who achieve BPHR at Week 24. Planned start Mar 2026; status: authorised.
02
Drugs
felzartamab
03
Conditions
kidney allograft rejectionmicrovascular inflammation (MVI)
Beyond the preview
Go deeper on 2025-521742-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521742-15-00.